Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Our previous work fails to show any
2025-01-24

Our previous work fails to show any maternal effect with blockade of 5-HT2A receptor, as acute and repeated treatment of MDL100907 does not alter maternal behavior at the behaviorally active doses (Chen et al., 2014). In the present study, MDL100907 pretreatment attenuated the maternal disruptive ef
-
urea AdipoRon is an orally active
2025-01-24

AdipoRon is an orally active, synthetic small molecule that activates adiponectin receptor (AdipoR). It mimics the antidiabetic effects of adiponectin, exhibiting its effect through the activation of AMPK and PPARα pathways via AdipoR1 and AdipoR2, respectively (Fig. 2) [62]. AdipoR activation has r
-
br Free entry equilibrium At stage of
2025-01-24

Free entry equilibrium At stage 2 of the game, n ≥ 2 firms simultaneously decide whether or not to enter the industry. Market entry involves a sunk fixed cost f > 0, which we assume cannot be subtracted from the tax base. Our assumption reflects that deductions of market entry costs are often inc
-
During the year study period of men
2025-01-24

During the 4-year study period, 19.9% of men in the dutasteride group developed prostate cancer as compared to 25.1% in the placebo group, which represents an absolute risk rotenone of 5.1% for men taking dutasteride (Pe weighed against the prospect of undesirable sexual side effects and decreased
-
Finasteride was the first steroidal reductase inhibitor appr
2025-01-24

Finasteride (13) was the first steroidal 5α-reductase inhibitor approved by the US Food and Drug Administration (FDA) in 1992 for treatment of BPH. In fact, long term clinical studies with this drug demonstrated a sustained reduction of the prostatic specific antigen and an overall improvement in BH
-
Various cardiovascular diseases show a high occurrence
2025-01-23

Various cardiovascular diseases show a high occurrence of autophagosomes. Whereas basal autophagy is required for the proper functioning of cardiomyocytes [82], the deletion of Atg5 gene in myocardium shows a high risk of cardiomyopathy [83]. Hamacher et al. observed that an upregulation of Bnip3, a
-
br Materials and methods br Results and
2025-01-23

Materials and methods Results and discussion Conclusion The preparation of acrylic nanoparticles as aminosugar carriers could not be achieved by direct functionalization of poly(t-butyl acrylate) particles with saccharide groups. A four-step procedure starting from a protected derivative of
-
CAY10603 On the other hand oxygen concentration in tumor
2025-01-23

On the other hand, oxygen concentration in tumor tissue also depends on its consumption rate by tumor cells, which decrease will also lead to alleviation of hypoxia. This fact is not taken into account in the majority of studies on the topic, although it is well-known that antiangiogenic therapy doe
-
TEM-1 beta-lactamase br STAR Methods br Acknowledgments We t
2025-01-23

STAR★Methods Acknowledgments We thank Simcere Pharmaceuticals, Nanjing, China, for providing a rabbit anti-VEGF neutralizing monoclonal antibody. We thank Dr. Schlisio in the Ludwig Institute for Cancer Research, Karolinska Institute, for assistance with hypoxia assay. Y.C.’s laboratory is sup
-
From a clinical utility standpoint this
2025-01-23

From a clinical utility standpoint, this study showed that AR can be useful in the GATA3-positive tumor of unknown origin setting. Epidemiologically, in this setting, the top 2 diagnoses in the differential diagnosis are metastatic carcinoma of breast origin or urothelial origin [18]. Seven out of 1
-
Detailed analysis of the dose
2025-01-23

Detailed analysis of the dose dependence of Aβ effects revealed that at low amounts, Aβ can also act as a positive regulator of presynaptic activity, enhancing the neurotransmitter release probability and increasing the neuronal excitability [2]. The facilitator effects of low Aβ dose on excitatory
-
br Concluding remarks Enhanced membrane
2025-01-23

Concluding remarks Enhanced membrane binding upon calcium stimulation in Olcegepant receptor suggests a pre-requisite step that involves a conformational change in LOX. This might facilitate it to tether to the membrane and regulate enzyme activity. The calcium binding loops and the putative act
-
The lactam emerged as lead candidate due to
2025-01-23

The lactam (6) emerged as lead candidate due to its high selectivity, outstanding potency (against ALK or in clinically known ALK mutants), low in vitro clearance, and low efflux potential. The lactam (6) was selected for further profiling against the resistant ALK mutants. Preclinical rat pharmacok
-
br Regulation of AHR Activity AHR activity
2025-01-23

Regulation of AHR Activity AHR activity is regulated in various ways. First, AHR protein levels are controlled via ubiquitin-mediated proteosomal degradation: Ligand binding induces AHR ubiquitination and subsequent degradation by the proteasome [5]. AIP, a component of the AHR chaperone complex,
-
Mass spectrometry MS analysis and selective enrichment metho
2025-01-22

Mass spectrometry (MS) analysis and selective enrichment methods of phosphorylated proteins are powerful tools that can help address these challenges. Recent advances in MS have made it possible to analyze signaling pathways by facilitating high-throughput identification of phosphorylation sites wit
16219 records 26/1082 page Previous Next First page 上5页 2627282930 下5页 Last page